C3
Complement C3
As of the edition of 20 October 2026, C3 (complement C3, UniProt P01024) has 3 drugs tested at it and 5 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01024
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 80
- Disease areas
- Eye; Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Immune system; Cancer; Hormones; Nervous system
- Registered trials of its drugs
- 37
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pegcetacoplan | Marketed | Phase 4 | Ends 2033 |
| AL-78898A | Stopped | Phase 2 | none listed |
| AMY-101 | Active | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Engaged | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Alcon | Route A |
| Swedish Orphan Biovitrum | Route B |
| Biogen | Route B |
The other 2 companies at C3
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at C3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.